Stifel Nicolaus Increases Incyte (NASDAQ:INCY) Price Target to $123.00

Key Points

• Stifel Nicolaus raised its price target on Incyte to $123 (from $120) and kept a "buy" rating, implying about a 21.7% upside, while the Street consensus average target remains lower at $105.06 amid mixed analyst ratings.
• Incyte reported a strong Q1 beat — $1.81 EPS and $1.27B revenue, up ~21% year-over-year — driven by demand for Jakafi and Opzelura, and is preparing four product launches over the next 12 months.
• Despite the quarterly beat, management's 2026 sales guide of roughly $4.77B–$4.94B is below Street estimates (~$5.6B) and the company faces regulatory scrutiny over promotional claims for Niktimvo, posing near-term valuation and compliance risks.

Incyte (NASDAQ:INCY - Get Free Report) had its target price increased by analysts at Stifel Nicolaus from $120.00 to $123.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. Stifel Nicolaus' price objective points to a potential upside of 21.68% from the company's previous close.

Other equities research analysts also recently issued reports about the stock. The Goldman Sachs Group reissued a "neutral" rating and issued a $90.00 price objective on shares of Incyte in a research report on Thursday, January 8th. UBS Group decreased their price objective on shares of Incyte from $104.00 to $94.00 and set a "neutral" rating for the company in a research report on Wednesday, March 25th. TD Cowen reiterated a "buy" rating on shares of Incyte in a research note on Tuesday, January 13th. Piper Sandler raised their price target on Incyte from $102.00 to $110.00 and gave the company an "overweight" rating in a research note on Friday, February 6th. Finally, Oppenheimer reaffirmed a "market perform" rating on shares of Incyte in a report on Wednesday. Ten investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $105.06.

Incyte Stock Performance

Shares of INCY opened at $101.08 on Wednesday. The stock has a 50-day simple moving average of $95.92 and a 200-day simple moving average of $98.76. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.32. The stock has a market capitalization of $20.12 billion, a PE ratio of 15.96, a PEG ratio of 0.77 and a beta of 0.85. Incyte has a 1 year low of $57.77 and a 1 year high of $112.29.

Incyte (NASDAQ:INCY - Get Free Report) last released its earnings results on Tuesday, April 28th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.41. The firm had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.23 billion. Incyte had a net margin of 25.03% and a return on equity of 26.34%. The business's quarterly revenue was up 20.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.16 earnings per share. On average, analysts predict that Incyte will post 6.46 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Pablo J. Cagnoni sold 18,667 shares of the company's stock in a transaction on Friday, April 17th. The shares were sold at an average price of $96.50, for a total value of $1,801,365.50. Following the completion of the transaction, the insider owned 262,692 shares in the company, valued at approximately $25,349,778. This represents a 6.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 17.80% of the company's stock.

Institutional Investors Weigh In On Incyte

Institutional investors and hedge funds have recently bought and sold shares of the stock. Norges Bank purchased a new position in shares of Incyte during the fourth quarter worth about $122,893,000. Caisse de depot et placement du Quebec lifted its holdings in shares of Incyte by 264.5% in the 3rd quarter. Caisse de depot et placement du Quebec now owns 1,498,013 shares of the biopharmaceutical company's stock valued at $127,046,000 after purchasing an additional 1,087,091 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Incyte by 6,586.4% in the 4th quarter. Marshall Wace LLP now owns 1,072,491 shares of the biopharmaceutical company's stock valued at $105,930,000 after purchasing an additional 1,056,451 shares during the period. Wellington Management Group LLP boosted its position in shares of Incyte by 3,406.8% in the 4th quarter. Wellington Management Group LLP now owns 739,378 shares of the biopharmaceutical company's stock valued at $73,028,000 after purchasing an additional 718,294 shares during the period. Finally, Northwestern Mutual Wealth Management Co. grew its stake in Incyte by 5,218.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 596,840 shares of the biopharmaceutical company's stock worth $58,950,000 after buying an additional 585,618 shares during the last quarter. 96.97% of the stock is owned by hedge funds and other institutional investors.

Incyte News Summary

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q1 beat: Incyte reported $1.81 EPS and $1.27B revenue, topping estimates and showing ~21% y/y revenue growth driven by strong demand for its cancer and dermatology franchises. Incyte beats first-quarter estimates on strong demand for cancer drugs
• Positive Sentiment: Product momentum: Management flagged Jakafi and rising Opzelura demand as major contributors to the beat and near-term growth. INCY Q1 Earnings and Revenues Beat Estimates
• Positive Sentiment: Pipeline launch cadence: Incyte says it is preparing four product launches over the next 12 months, which could meaningfully expand top-line opportunities if approvals/commercial execution go as planned. Incyte outlines $4.77B-$4.94B 2026 net sales while preparing four launches over 12 months
• Neutral Sentiment: CFO change: Incyte named Suketu (Suky) Upadhyay as CFO — a governance/operational update that removes uncertainty around the finance role but is not an immediate earnings driver. Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
• Neutral Sentiment: Investor outreach: Company scheduled presentations at upcoming investor conferences — useful for transparency and replaying the quarter’s messages but not an immediate catalyst. Incyte to Present at Upcoming Investor Conferences
• Neutral Sentiment: Clinical readouts: A JAK inhibitor picked up Phase 3 wins in vitiligo, but analysts note it still faces headwinds from entrenched competitors (e.g., AbbVie’s Rinvoq), so upside is conditional. Incyte’s JAK inhibitor scores phase 3 vitiligo wins but can’t quite shake Rinvoq
• Negative Sentiment: Below-consensus FY revenue guide: Incyte outlined 2026 net sales roughly $4.77B–$4.94B, noticeably below Street estimates (~$5.6B), introducing near-term valuation pressure despite the quarter’s beat. Incyte outlines $4.77B-$4.94B 2026 net sales while preparing four launches over 12 months
• Negative Sentiment: Regulatory/marketing scrutiny: The FDA publicly criticized Incyte over allegedly misleading promotional claims for Niktimvo, which raises compliance risk and potential reputational/labeling consequences. FDA lambasts Incyte over ‘misleading’ Niktimvo claims
• Negative Sentiment: Mixed sentiment on upcoming drugs: Coverage flagged doubts about povorcitinib and other near-term prospects, which could temper growth assumptions if launch momentum disappoints. Incyte earnings on deck: Povorcitinib prospects meet Q1 reality

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company's flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.